Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Meister Keith A.

Wedel Christensen Jakob

The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.

Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight

The cancer biomarkers market is projected to grow from USD 23.22 billion in 2026 to USD 35.16 billion by 2031, with a CAGR of 8.65%. Growth is driven by increasing cancer prevalence, rising adoption of personalized medicine, advancements in molecular diagnostics, and expanding use of companion diagnostics. North America leads the market while Asia-Pacific emerges as a high-growth region.

Cancer Biomarkers Market Outlook 2026–2031: Growing at a 8.65% CAGR, Driven by Precision Oncology and Early Detection Demand, Says Mordor Intelligence

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight

The AI in life sciences market is projected to grow from USD 2.2 billion in 2025 to USD 11.5 billion by 2034, driven by accelerated drug discovery, precision medicine adoption, and increasing healthcare data availability. North America leads with 44.78% market share, while Europe and Asia-Pacific show significant growth potential. Major pharmaceutical and technology companies are investing heavily through partnerships and AI-enabled platforms.

Global AI in Life Sciences Market Gearing Up for Outstanding Expansion at a CAGR of ~20% by 2034 | DelveInsight

The personalized medicine market is projected to grow from USD 524 billion in 2025 to USD 1 trillion by 2034, driven by advances in genomics, AI-powered diagnostics, and targeted therapies. North America leads the market with 41% share, while Asia-Pacific emerges as a key growth engine. Major pharmaceutical and biotech companies are investing heavily in precision medicine solutions across oncology, rare diseases, and chronic conditions.

Global Personalized Medicine to Transform Modern Healthcare and Cross USD 1 Trillion by 2034 | DelveInsight

Research-driven thematic investor & swing trader. Not financial advice

Subscribe: https://t.co/tRfuPuBAXn

Illumina Inc (ILMN) Stock Price, Analysis & Trade Signals